secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193125-25-175567
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Therapeutic Q2 net loss $20M; cash $287.4M; TX45 PH-ILD Phase 2 planned 2026
--------------------------------------------------------------------------------

- Net loss of $20.0M in Q2 2025 vs $12.7M in Q2 2024; R&D expenses rose to $17.2M from $7.1M.
- Cash and cash equivalents $287.4M as of June 30, 2025; expected cash runway into Q4 2028.
- TX45 Phase 1b Part A results: 19% reduction in PCWP, 18.5% improvement in cardiac output, >30% PVR reduction in CpcPH.
- Part B of TX45 Phase 1b in PH-HFrEF enrollment completed; topline results expected early Q4 2025.
- New PH-ILD Phase 2 trial for TX45 to start in 2026; TX2100 Phase 1 expected Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525175567/0001193125-25-175567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312525175567/d36621d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-175567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer